Specific internalization of targeted lipid-based nanoparticles to mantle cell lymphoma (MCL) cells
aCD38 lipid-nanoparticles internalized (LNPs) specifically to MCL cells (right panel).
Isotype-LNPs do not internalized to MCL cells (left panel)
Particles insides particles
SEM analysis of PLGA particles entrapping immunogenic peptide.
Ovarian cancer cells surface morphology visualized by scanning electron micrograph (SEM).
Transmission electron microscopy of mantle cell lymphoma exosomes
Mantle cell lymphoma patients’ exosomes were isolated from the culture media of MCL cells and analyzed by transmission electron microscopy (TEM) and immuno-electron microscopywith anti-CD81 followed by IgG 12-nm in diameter gold nanoparticle conjugated mAb.
Our lab is studying how to manipulate cells' functions in order to generate novel strategies to treat inflammatory diseases and cancers. We are combining multidisciplinary approaches including immunology, cell and molecular biology, genetics, protein engineering, material sciences, nanotechnology and computational techniques for drug discovery and potentially for therapeutics. In addition, we are developing nanomedicines by designing highly selective targeting moieties and novel nanocarriers, with an ultimate goal to translate some of our findings into clinical settings.
We are particularly interested in
- Developing novel strategies for targeted drug delivery.
- Probing and manipulating the immune system with nanomaterials.
- Developing non-invasive theranostic systems for inflammatory bowel diseases and blood cancer.
- Studying the role of cell cycle regulators during inflammatory bowel diseases and blood cancers.
- Investigating novel cancer multidrug resistance inhibitors.
- Studying novel approaches to target adult stem cells (hematopoietic; bulge, cancer).
- Harnessing RNAi as a tool for drug discovery and for therapeutic applications.
- Developing tools to study immuno-nanotoxicity.
- Investigating polysaccharides as building blocks for Nanotherapeutics